Prelude Therapeutics is a privately held biotechnology company focused on discovering and developing new medicines targeting chromatin function to treat cancer and rare diseases.
Location: United States, Delaware, Wilmington
Total raised: $110M
Investors 2
| Date | Name | Website |
| - | The Innova... | innovation... |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.08.2020 | Series C | $50M | - |
| 12.06.2019 | Series B | $60M | - |
Mentions in press and media 11
| Date | Title | Description |
| 15.05.2025 | AI-powered drug development startup Pathos AI closes $365M investment Your vote of support is important to us and it helps us keep the content FREE. One click below supports our mission to provide fre... | Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding. The company didn’t disclose the investors in the Series D round. According to Fi... |
| 23.07.2024 | QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs | SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX, a computational drug discovery company, today announced a collaboration with Prelude Therapeutics, a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncolo... |
| 05.03.2024 | Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting | - |
| 01.08.2023 | JLL to lease Delaware's Innovation Space | WILMINGTON, Del .- JLL has entered an exclusive arrangement with The Innovation Space™ to match tenants with the impressive offerings of the organization’s multi-use lab space, offices and common areas. The Innovation Space features more th... |
| 11.05.2021 | PRELUDE THERAPEUTICS INCORPORATED Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update | - Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2... |
| 25.08.2020 | Prelude Therapeutics just raised a $50M Series C | In 2019, Prelude Therapeutics, the Wilmington-based biopharmaceutical oncology company, landed $60 million in Series B funding. Now, the company has raised a $50 million Series C to continue its growth, its leadership announced on Monday. I... |
| 24.08.2020 | Prelude Therapeutics Announces Closing of $50M Series C Financing | - |
| 24.08.2020 | Prelude Therapeutics Closes $50M in Series C | WILMINGTON, DE, Prelude Therapeutics announced that it has completed a $50M Series C financing round led by OrbiMed Advisors and Fidelity Management & Research. >> Click here for more funding data on Prelude Therapeutics >&... |
| 12.06.2019 | Prelude Therapeutics Raises $60M in Series B Funding | Prelude Therapeutics, a Wilmington, Del.-based clinical-stage biopharmaceutical company, secured $60m in Series B financing. The round, which brought total funding to date to $95m, was co-led by existing institutional investors, including O... |
| 12.06.2019 | Prelude Therapeutics nabs $60M series B, gains biopharma veteran as CMO | Prelude Therapeutics has completed a $60 million series B round, boosting its total raised to $95 million as it looks to deepen its cancer work into the clinic. The Wilmington, Delaware-based biotech also announced that David Mauro, M.D., P... |
Show more